Dr Reddy's Laboratories announces share buyback offer

Pharmaceutical major, Dr Reddy's Laboratories Limited, today announced the schedule for buyback of equity shares from public for about Rs 1,569.41 crore beginning April 18, 2016.

The company said it proposes to acquire 44,84,049 shares (around 4.48 million shares) of face value of Rs 5 at a maximum buyback price of Rs 3,500 per share. These shares represent a maximum buyback size of 14.9% of paid up equity shares of the company.

On February 17, the Board of Directors of Dr Reddy's had approved a decision to go for buyback of shares using the company’s reserves. On April 1, the company had taken shareholders’ approval for the same through a postal ballot.

The maximum buyback price fixed by the company represents 18.6% of the two week average closing price of shares. The company informed the stock exchanges that it would complete the proposed buyback of shares within six months.

The company scrip opened at Rs 3,079 Tuesday on BSE as compared to the previous close of Rs 3,028.


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel